Company news

Harrow, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

March 16, 2025

Harrow Launches VEVYE® Access for All

March 16, 2025

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

March 10, 2025

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

March 2, 2025

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

January 26, 2025

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

January 6, 2025

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

November 20, 2024

Harrow Announces Participation in Upcoming Investor Conferences

November 14, 2024

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

November 12, 2024

Harrow Announces Third Quarter 2024 Financial Results

November 12, 2024

Harrow Announces Market Access Wins for VEVYE®

November 11, 2024

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products

November 6, 2024

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

October 30, 2024

Harrow Relaunches TRIESENCE®

October 2, 2024

Harrow Announces Nashville Expansion

September 24, 2024

Harrow to Present at Three Investor Conferences in September in New York

September 2, 2024

Harrow Announces Second Quarter 2024 Financial Results

August 6, 2024

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024

July 24, 2024

Harrow to Attend 2024 ASRS Annual Meeting

July 11, 2024

Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products

July 8, 2024

Harrow Provides TRIESENCE® Relaunch Update

June 19, 2024

Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study

June 4, 2024

Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

May 12, 2024

Harrow Announces First Quarter 2024 Financial Results

May 12, 2024

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024

April 24, 2024

Harrow Announces Fourth Quarter and Year-End 2023 Financial Results

March 18, 2024

Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024

March 4, 2024

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products

February 14, 2024

Harrow Announces New Appointments to its Board of Directors

January 28, 2024

Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease

January 10, 2024

Melt Pharmaceuticals Provides Corporate Update

January 2, 2024

Harrow Partners with Leading Healthcare Market Access Technology Platforms

January 2, 2024

Harrow Completes Transfer of the TRIESENCE® New Drug Application

November 28, 2023

Harrow to Present at Two Investor Conferences in November

November 19, 2023

Harrow Announces Third Quarter 2023 Financial Results

November 12, 2023

Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023

October 29, 2023

Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.

October 23, 2023

Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.

September 28, 2023

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation

September 25, 2023

Harrow Announces Second Quarter 2023 Financial Results

August 8, 2023

Harrow Launches VIGAMOX® in the U.S.

July 30, 2023

Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023

July 25, 2023

Harrow Prices $60 Million Public Offering of Common Stock

July 18, 2023

Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance

July 17, 2023

Harrow Announces Proposed Public Offering of Common Stock

July 17, 2023

Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq

July 17, 2023

Harrow Acquires Santen’s Branded Ophthalmic Portfolio

July 17, 2023

Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023

May 16, 2023

Harrow Announces First Quarter 2023 Financial Results

May 10, 2023

Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

May 3, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 56 decks. Every deck is listed under its year.